title: Evaluation of 3,3'-diindolylmethane with gardasil quadrivalent HPV vaccine in K14-HPV16-transgenic mice cervical histology.
abstract: BACKGROUND
  The effects of 3,3'-diindolylmethane (DIM) together with the Gardasil vaccine on cervical histology were evaluated using the K14-HPV16-transgenic mouse model. The possibility that DIM could enhance the efficacy of this preventive vaccine in this model was explored.
  
  
  METHODS
  Transgenic mice were given 1000 mg/kg of DIM in the diet for 28 weeks. The mice were injected with Gardasil Quadrivalent HPV vaccine. Some mice were sacrificed at 28 weeks. Other groups were removed from the DIM diet after 28 weeks to a diet with no DIM for either 4 or 8 weeks.
  
  
  RESULTS
  Cervical histology indicated that a high percentage of transgenic mice fed DIM and vaccinated with Gardasil manifested normal cervical epitheliums at 4 weeks after DIM discontinuation.
  
  
  CONCLUSIONS
  Vaccination pre-supplemented with DIM may provide with a window of protection of at least four weeks in this transgenic model. However, extrapolation to the effect in humans is beyond the limited scope of the histological data presented here.
authors.affiliation: Ph.D. The David and Alice Jurist Institute for Research, Hackensack University Medical Center. Hackensack, NJ, U.S.A. dsepkovic@HackensackUMC.org.
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Sepkovic
authors.forename: Doris V
authors.initials: DV
authors.lastname: Pagan
authors.forename: Johann
authors.initials: J
authors.lastname: Stein
authors.forename: Antoine D
authors.initials: AD
authors.lastname: Carlisle
authors.forename: H Barbara
authors.initials: HB
authors.lastname: Ksieski
authors.forename: Karen
authors.initials: K
authors.lastname: Auborn
authors.forename: Themba
authors.initials: T
authors.lastname: Nyirenda
authors.forename: H Leon
authors.initials: HL
authors.lastname: Bradlow
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000494:pharmacology; D002584:Cervix Uteri / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D052162:Human papillomavirus 16 / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008822:Mice, Transgenic; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control; D002578:Uterine Cervical Dysplasia / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control
chemical_list: D016588:Anticarcinogenic Agents; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D007211:Indoles; D053918:Papillomavirus Vaccines; C016392:3,3'-diindolylmethane